Sensus Healthcare, Inc. (SRTS)
NASDAQ:SRTS
Want to see SRTS full AI Analyst Report?
Top Page
Sensus Healthcare
(NASDAQ:SRTS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▼(-14.77% Downside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by materially deteriorated financial performance (declining revenue, sharply negative margins) and renewed cash burn, alongside bearish technicals with the stock trading below key moving averages. Partly offsetting these risks are a strong, low-debt balance sheet and a mixed-but-improving earnings-call outlook featuring reimbursement-driven catalysts and guidance for sequential revenue improvement toward profitability, though execution and customer concentration remain key uncertainties.
Positive Factors
Balance Sheet Strength
Sensus’s strong liquidity (cash of $18.3M) and minimal leverage give durable financial flexibility to fund commercial expansion, absorb losses during the transition to recurring revenue, and invest in go-to-market initiatives without immediate reliance on external financing.
Negative Factors
Profitability Deterioration
A sharp swing back to sizable losses and meaningful gross-margin compression indicate structural pressure on pricing, mix or cost control. Sustained negative margins reduce reinvestment capacity and threaten the company’s ability to restore ROE without durable recovery in volumes or pricing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Sensus’s strong liquidity (cash of $18.3M) and minimal leverage give durable financial flexibility to fund commercial expansion, absorb losses during the transition to recurring revenue, and invest in go-to-market initiatives without immediate reliance on external financing.
Read all positive factors
Sensus Healthcare Key Performance Indicators (KPIs)
Sensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$52.51M
Dividend YieldN/A
Average Volume (3M)69.33K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-42.94%
EPS Growth-529.29%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.47
Shares Outstanding16,462,059
10 Day Avg. Volume118,191
30 Day Avg. Volume69,328
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.35
Price to Sales (P/S)2.36
P/FCF Ratio195.73
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit4.07
Enterprise Value/Ebitda-4.04
Forecast
1Y Price Target
$5.67Price Target Upside60.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$25.14M
Sensus Healthcare Business Overview & Revenue Model
Company Description
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatmen...
How the Company Makes Money
Sensus Healthcare generates revenue primarily from selling its radiation therapy systems (capital equipment) to medical practices and treatment centers. In addition to upfront system sales, the company earns recurring revenue from the ongoing use ...
Sensus Healthcare Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but strategically constructive picture: strong operational catalysts (dedicated CPT codes, ~300% reimbursement increase, SensusLink launch, shipment activity, 8% treatment volume growth, solid cash position) that support a transition toward recurring revenue and broader adoption, contrasted with a sharp year-over-year revenue decline (~59%), significant margin compression (gross margin down to 29.2% from 52.2%), a larger adjusted EBITDA loss, and near-term revenue recognition/mix headwinds. Management is optimistic about sequential improvement (Q2 > Q1 and H2 > H1) and achieving full‑year profitability, but near-term financial performance remains challenged during the transition.Positive Updates
Dedicated CPT Codes Implemented
New dedicated CPT codes for superficial radiotherapy effective Jan 1, 2026; management reports clearer reimbursement environment and increased market confidence, enabling broader adoption and simpler coding for dermatology SRT.
Negative Updates
Revenue Decline Year‑Over‑Year
Q1 revenue of $3.4 million versus $8.3 million in prior-year period, a decline of approximately 59.0%, primarily driven by no sales to the company's historically largest customer in the quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
Dedicated CPT Codes Implemented
New dedicated CPT codes for superficial radiotherapy effective Jan 1, 2026; management reports clearer reimbursement environment and increased market confidence, enabling broader adoption and simpler coding for dermatology SRT.
Read all positive updates
Company Guidance
Management guided that Q2 revenue should be higher than Q1 ($3.4M) and the second half of 2026 should exceed the first half as the company builds toward full‑year profitability with sequential quarter‑over‑quarter improvement; Q1 results included revenue $3.4M (vs. $8.3M PY; excluding the largest PY customer revenue was $2.7M), gross profit $1.0M and gross margin 29.2% (vs. 52.2% PY), cost of sales $2.4M, adjusted EBITDA -$4.2M (vs. -$2.5M PY), net loss $2.6M or $0.16 per share, cash $18.3M, no debt and inventory $16.5M, and operational highlights of 14 systems shipped (10 direct, 4 FDA/rental), ~965 total installed systems, ~70% of Q1 shipments purchased vs. FDA, treatment volumes +8% YoY, 18 active FDA sites and 9 pending, rollout of SensusLink (live) to drive recurring revenue (historically ~10% of revenue) from FDA, service and software, a ~300% increase in the per‑fraction delivery code, an average radiation‑physics reimbursement of ~$93.85/week (~$930 over ten weeks), and the note that the largest 2025 customer is not included in 2026 guidance (would be upside if they return).Sensus Healthcare Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.53M | 27.48M | 41.81M | 24.41M | 44.53M | 27.04M |
| Gross Profit | 8.51M | 11.87M | 24.43M | 14.06M | 29.63M | 16.99M |
| EBITDA | -8.57M | -9.92M | 8.52M | 79.00K | 15.34M | 4.73M |
| Net Income | -7.77M | -7.72M | 6.65M | 485.00K | 24.24M | 4.12M |
Balance Sheet | ||||||
| Total Assets | 51.55M | 53.04M | 62.16M | 53.71M | 56.73M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 18.33M | 22.08M | 22.06M | 23.15M | 25.52M | 14.52M |
| Total Debt | 407.00K | 680.00K | 602.00K | 783.00K | 1.02M | 225.00K |
| Total Liabilities | 6.00M | 4.94M | 6.34M | 4.87M | 8.67M | 6.22M |
| Stockholders Equity | 45.54M | 48.10M | 55.83M | 48.84M | 48.07M | 26.02M |
Cash Flow | ||||||
| Free Cash Flow | -623.00K | 332.00K | -1.11M | -2.37M | -1.57M | -414.00K |
| Operating Cash Flow | -548.00K | 528.00K | -831.00K | -2.15M | -1.41M | -286.00K |
| Investing Cash Flow | -192.00K | -196.00K | -276.00K | -187.00K | 14.84M | 129.00K |
| Financing Cash Flow | -5.00K | -305.00K | 15.00K | -40.00K | -2.43M | -231.00K |
Sensus Healthcare Technical Analysis
Negative
3.52
Price Trends
3.94
Negative
4.24
Negative
3.89
Negative
Market Momentum
-0.22
Positive
33.78
Neutral
31.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Negative. The current price of 3.52 is below the 20-day moving average (MA) of 3.64, below the 50-day MA of 3.94, and below the 200-day MA of 3.89, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 33.78 is Neutral, neither overbought nor oversold. The STOCH value of 31.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRTS.
Sensus Healthcare Risk Analysis
Sensus Healthcare disclosed 24 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensus Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $147.91M | -3.06 | -101.28% | ― | 30.66% | 25.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $52.51M | -6.24 | -15.79% | ― | -42.94% | -529.29% | |
47 Neutral | $16.14M | -1.30 | -211.73% | ― | 8.92% | 17.49% | |
46 Neutral | $28.94M | -1.73 | -165.13% | ― | 7.72% | 34.39% | |
43 Neutral | $7.07M | -0.16 | -247.60% | ― | ― | 36.00% | |
41 Neutral | $46.84M | 103.59 | -81.52% | ― | 54.38% | 7.25% |
* Healthcare Sector Average
SRTS
Sensus Healthcare
3.19
-1.50
-31.98%
NSPR
InspireMD
1.00
-1.53
-60.47%
CTSO
Cytosorbents
0.46
-0.38
-45.56%
RBOT
Vicarious Surgical
0.99
-6.43
-86.63%
HYPR
Hyperfine
1.49
0.95
173.90%
ICCM
Icecure Medical
0.24
-0.88
-78.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.